It was a pleasure to meet with Prof. Peter Pappas (University of Alabama at Birmingham, Birmingham, AL, USA) to discuss the unmet needs in the treatment of Candida infections.
The abstract entitled: ‘Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)’ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
Questions:
- Could you give us an overview of the health burden of Candida infections? (0:34)
- What are the unmet needs in the treatment of Candida infections? (2:26)
Disclosures: Peter Pappas receives research support from Cidara, Mayne, Astellas, Gilead and Scynexis; and is also a Scientific advisor for Scynexis, Matinas and F2G.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of IDWeek, Virtual 2021
